Ausgangsorgan Dysfunktion, die Standard-R-CHOP-Dosen: LVEF < 50% (Anthracyclin con...
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | RF-DLBCL-ORGAN-DYSFUNCTION |
|---|---|
| Art | Warnhinweis |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Erkrankungen | DIS-DLBCL-NOS |
| Quellen | SRC-ESMO-DLBCL-2024 SRC-NCCN-BCELL-2025 |
Ursprung der Roten Flagge
| Begriffsbestimmung | Baseline organ dysfunction precluding standard R-CHOP doses: LVEF <50% (anthracycline contraindicated), CrCl <30 mL/min (severe cyclophosphamide / methotrexate dose constraints), bilirubin >3× ULN (vincristine / doxorubicin metabolism), or DLCO <60% (lung-toxicity risk on CHOP-based therapy). |
|---|---|
| Klinische Richtung | Eskalation |
| Kategorie | Organdysfunktion |
| Schaltet Algorithmus | ALGO-DLBCL-1L |
Logik auslösen
{
"any_of": [
{
"comparator": "<",
"finding": "lvef_percent",
"threshold": 50
},
{
"comparator": "<",
"finding": "creatinine_clearance_ml_min",
"threshold": 30
},
{
"comparator": ">=",
"finding": "bilirubin_ratio_to_uln",
"threshold": 3
},
{
"comparator": "<",
"finding": "dlco_percent",
"threshold": 60
}
],
"type": "lab_value"
}
Anmerkungen
LVEF <50%: substitute liposomal doxorubicin or omit anthracycline (R-CEOP using etoposide; or R-GCVP). CrCl <30: cyclophosphamide reduce 25-50% per institutional renal-dosing protocol; HD-MTX contraindicated for CNS prophylaxis (use IT only). DLCO <60%: document baseline carefully; pulmonary toxicity is uncommon at standard CHOP cycles but accumulates at salvage. This RF de-escalates toward R-CHOP standard from Pola-R-CHP intensification when both fire (high IPI + organ dysfunction common in elderly).
Verwendet von
Algorithmen
ALGO-DLBCL-1L- ALGO-DLBCL-1LALGO-DLBCL-2L- ALGO-DLBCL-2L
Kapitel des Handbuchs
HB-DLBCL-1L- Diffuse große B-Zell-Lymphom: First-Line-Reinigung
Handbuchfragen
HQ-DLBCL-1L-002- HQ-DLBCL-1L-002